
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics is showing strong potential for success in autoimmune diseases, particularly with its lead candidate KYV-101, which has shown positive results in a Phase 1 trial for stiff-person syndrome (SPS). The company has received FDA alignment for its regulatory filings and is on track to submit a BLA in 1H26, with a potential commercial launch in 2027. The company's financials show controlled spending and a solid cash runway, mitigating dilution risks. However, there are still risks associated with the durability of responses and potential failures in other indications. Overall, the company's strong clinical data and promising outlook make it a positive investment opportunity.
Bears say
Kyverna Therapeutics is facing a challenging market for its product, KYV-101, as the RA field already has many chronic treatment options available. The limited data from the Phase 1 dataset and the need to show a significant and durable advantage compared to existing treatments in terms of efficacy, safety, logistics, and cost, make it difficult for investors to justify the company's position in the market. Even though there is potential for incremental upside with their EULAR update for RA, the main focus and valuation for the company lies in the execution of their product for skin-predominant SPS and gMG.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares